XCUR trade ideas
$XCUR Next Target PTs .45-1.20-1.90 and higherExicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
Exicure (NASDAQ: $XCUR) Could Double Or More In Near-Term! 🎯Exicure, Inc., a clinical-stage biotechnology company, develops therapeutics for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. Its drug candidate includes cavrotolimod (AST-008) that is in a Phase 1b/2 clinical trials in patients with advanced solid tumors. The company is also developing XCUR-FXN, an SNAÂbased therapeutic candidate that is in preclinical trials for the treatment of Friedreich's ataxia; XCUR17, an SNA that targets the messenger RNA (mRNA) encoding interleukin 17 receptor alpha; and AST-005, an SNA targeting TNF for the treatment of mild to moderate psoriasis. It has a collaboration, option, and license agreement with Allergan Pharmaceuticals International Limited to develop SNA-based treatments for hair loss disorders; license and development agreement with DERMELIX, LLC to research, develop, and commercialize its technology for the treatment of netherton syndrome; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. The company was founded in 2011 and is headquartered in Chicago, Illinois.
$XCUR Exicure Inc On Breakout watchlist
200ma break pre-market
downtrend is major resistance.
RSI & Momentum Bullish
targets as per chart
XCUR: Got Ways to Go $3.30 TargetFirst off, please don't take anything I been saying seriously or as financial advice. As always, this is on an opinion based basis. That being said XCUR has a reasonable target of reaching $3.30 soon in my opinion. It is still on a positive retracement wave looking at the entire chart history, and the bullish run looks to be continuing. The only reason I would enter now, short at $3.30 (if I was to do this trade), would be to reinvest in another stock or a dip.
Exicure, Inc uptrend targets Exicure, Inc. is a clinical-stage biotechnology company, which engages in the discovery, research, and development of treatments based on spherical nucleic acid technology (SNA). It focuses on neurology, immuno-oncology, inflammatory diseases, and other genetic disorders. The company was founded by Chad A. Mirkin and Colby Shad Thaxton in 2011 and is headquartered in Skokie, IL.
Exicure Inc. P-Modeling Pt Z. The Cajun Ship of ObliterationWelcome Hyperspace Archaeologists,
Come for the laughs, stay for the Art.
___________________
Find the "we are here" bubble.
I am most likely wrong...
Meh . Who cares.
but what... if..
good enough for me! All in. #pewpeww
__________________________________
Trade Taken:
Entry Range is $2.38 - $2.45
Target $8.60
Hold until April 2021
Technical.
One Cajun Ship nestled w/
Root-1-2-3-4-5 &
Root-W-X-Y-X-Z
TimeFrame: 1-Day.
_____________________________
Failure is a necessary presupposition to success.
Laugh with me into madness.
Thanks for Pondering the Unknown with Me,
Glitch420
*Disclaimer: If you seizure prone, turn the brightness all the way up for extra eye bleed. This is financial advice.
